Clinical Trial Update: TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions [Phase 3]

View source ↗

Summary

Phase 3 TAXUS Atlas study evaluating the TAXUS Liberté SR paclitaxel-eluting stent for de novo coronary artery lesions has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• TAXUS Liberté SR Stent (paclitaxel-eluting stent)

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Coronary Artery Disease | Phase 3 | Status: COMPLETED